We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Beam Therapeutics

News List

Oxford Biomedica and Beam Therapeutics sign CAR-T deal pharmatimes
August 04, 2020
UK-based Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics for next-generation CAR-T therapeutics.
Beam Therapeutics licenses Bio Palette’s base editing technologies pharmaceutical-technology
June 05, 2019
Bio Palette has signed a cross-license agreement granting Beam Therapeutics a licence for its intellectual property (IP) to develop new therapeutics.
Beam Therapeutics, Bio Palette to develop microbiome-related therapeutics in Asia biospectrumasia
June 03, 2019
Bio Palette licenses base editing intellectual property to Beam Therapeutics for use in human therapeutics
Beam Therapeutics raises $135m to advance CRISPR technologies pharmaceutical-technology
March 08, 2019
US-based precision genetic medicines developer Beam Therapeutics has raised $135m in a series B funding round to drive the development of next-generation CRISPR technologies.
Beam Therapeutics raises $135m to advance CRISPR technologies pharmaceutical-technology
March 08, 2019
US-based precision genetic medicines developer Beam Therapeutics has raised $135m in a series B funding round to drive the development of next-generation CRISPR technologies.